Table 1 Clinical characteristics, outcomes and toxicities of CAR-T Phase III trials in large B cell lymphoma (LBCL).
From: Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
Axi-cel | Tisa-cel | Liso-cel | |
|---|---|---|---|
B cell target | CD19 | CD19 | CD19 |
Stimulatory Signal 1 | CD3ζ | CD3ζ | CD3ζ |
Stimulatory Signal 2 | CD28 | 4-1BB | 4-1BB |
Phase 3 Trial | Zuma-7 | Belinda | Transform |
Bridging Therapy | Not allowed | 83% received bridging; platinum-based | 64% received bridging; |
Median time from leukapheresis to infusion | 29 days | 52 days | 26 days |
ORR | 83% | 75% | 87% |
CRR | 65% | 46% | 74% |
Median PFS | 14.7 months | 3 months (EFS) | NR (18 m PFS = 58%) |
Median OS | NR | 15.3 months | NR (18 m OS = 73%) |
Median follow up | 47.2 months | 10 months | 17.5 months |
DOR | 26.9 months | – | NR |
FDA approval in LBCL | 2nd line: primary refractory or relapsed in one year LBCL ≥3rd line: relapsed refractory LBCL | 2nd line: not approved 3rd line: relapsed refractory LBCL | 2nd line: primary refractory or relapsed in one year LBCL. Patients with ≥1 PLT and in eligible for ASCT. ≥3rd line: relapsed refractory LBCL |
CRS grade ≥3 | 6% | 5% | 1% |
Neurologic AEs grade ≥3 | 21% | 2% | 4% |
